BD Celebrates Strong Growth with Fiscal Year 2026 Financial Results Announcement

BD Reports Financial Results for Q4 and Full Year Fiscal 2026

BD (Becton, Dickinson and Company), a significant player in the global medical technology industry, revealed its fourth quarter and full-year financial results for fiscal 2026, which concluded on September 30, 2026. The company reported a revenue of $5.3 billion in Q4, reflecting an increase of 5.4% when compared to the previous year. Notably, the revenue growth adjusted for foreign exchange was even more impressive at 5.6%.

For the entire fiscal year 2026, BD generated $19.5 billion in revenue, marking a growth of 4.9% compared to the prior year, with a 3.9% increase when currency fluctuations are accounted for. The company also reported an adjusted diluted earnings per share (EPS) of $12.70, up from the previous year, showcasing a strong performance across various sectors.

Tom Polen, CEO and President of BD, expressed confidence in the company's growth trajectory, stating, "We delivered a strong fourth quarter, with broad-based performance led by our key growth platforms. This fiscal year was pivotal as we completed our transformation into a more focused MedTech company, enhancing our operational capabilities and driving innovation."

Key Highlights from Fiscal Year 2026

1. Business Transformation: BD has successfully separated its Life Sciences business and focused on strengthening its core growth areas. This strategic shift aims to optimize their operations, accelerate innovation, and ultimately drive productivity.
2. Partnership with the U.S. Government: BD announced a historic partnership with the U.S. Government to enhance domestic manufacturing of essential medical products. This initiative involves a massive investment of $19 billion into U.S. manufacturing facilities, with a notable $3 billion allocated specifically for manufacturing expansion.
3. Innovative Solutions: The deployment of the BD® Vmax™ 160 Pharmacy Automation Robot in Fairview Health Services marks a critical step in advancing healthcare solutions in outpatient pharmacy operations across the U.S. The company also launched several new products, reinforcing its position in the interventional market.
4. Clinical Advancements: BD has made substantial progress in its vascular innovation sector, launching the BD® Liverty™ TIPS Stent Graft for patients with portal hypertension. Additionally, strong interim results from clinical trials for the BD® Revello™ Vascular Covered Stent underscore its commitment to improving patient outcomes.

Financial Overview

In Q4 fiscal 2026, BD reported a diluted EPS of $2.52, significantly higher than the $1.20 reported the previous year, indicating an increase of nearly 110%. Free cash flow increased to $2.9 billion, representing a robust 42.5% rise from the prior year. BD’s strong performance has instilled confidence as it prepares to enter fiscal year 2027.

Looking ahead, the company anticipates low single-digit growth in its revenue for fiscal year 2027, with an adjusted diluted EPS forecast between $13.10 and $13.30. BD's management is optimistic about its strategic investments and innovations, which are expected to enhance its competitive position in the market.

BD will hold its 2026 Investor Day on December 10th at the New York Stock Exchange, where it will discuss detailed aspects of its financial performance and strategic outlook.

Conclusion

BD emerges from fiscal 2026 with strong momentum and a clear vision for its future in the healthcare sector. With significant investments in innovation, strategic partnerships, and a focus on operational excellence, BD is well-positioned to thrive as a leading global medical technology company. For more insights and updates on BD, visit their official website or social media platforms.